Aspire Biopharma (ASBP) Stock Price, News & Analysis

Company Overview

Aspire Biopharma Inc. is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis. In addition to epinephrine, Aspire has in-licensed a portfolio of novel PDE3/4 inhibitor compounds intended for maintenance therapy in chronic obstructive pulmonary disease (COPD) and severe asthma. Aspire’s development strategy emphasizes efficient clinical pathways and leveraging existing safety data to accelerate regulatory review.

Founded in 2007 and headquartered in Henderson, Nevada, Aspire Biopharma serves the U.S. market while exploring international licensing and distribution opportunities. The company maintains partnerships with contract development and manufacturing organizations (CDMOs) to support scalable production of its inhalation devices and formulations. Aspire’s leadership team combines expertise in pharmaceutical R&D, regulatory affairs, and pulmonary device engineering to drive its product pipeline toward late-stage clinical and market readiness.

Through strategic collaborations and targeted R&D investments, Aspire aims to address unmet medical needs in emergency medicine and chronic respiratory care. By focusing on inhaled delivery of both established and novel compounds, the company seeks to offer differentiated treatment options that improve patient outcomes and streamline acute care interventions.

Key Stats

• Today's Range: $0.34 to $0.37
• 50-Day Range: $0.21 to $0.59
• 52-Week Range: $0.20 to $15.80
• Volume: 3.56 million shs
• Average Volume: 12.88 million shs
• Market Capitalization: $18.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ASBP Stock Analysis - Frequently Asked Questions

How have ASBP shares performed this year?

Aspire Biopharma's stock was trading at $0.4301 at the beginning of 2025. Since then, ASBP stock has decreased by 17.5% and is now trading at $0.3548.

How were Aspire Biopharma's earnings last quarter?

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) issued its earnings results on Wednesday, August, 13th. The company reported ($0.04) EPS for the quarter.

How do I buy shares of Aspire Biopharma?

Shares of ASBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASBP
• CIK: 1847345
• Web: N/A
• Phone: (561) 704-8527
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -737.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.17) per share
• Price / Book: -0.17

Miscellaneous

• Outstanding Shares: 49,530,000
• Free Float: 36,748,000
• Market Cap: $17.98 million
• Optionable: N/A
• Beta: 0.67